GLP-1 agonists (BYETTA) are now
included in the ADA/EASD algorithm
for the metabolic management of
type 2 diabetes
1
ADA/EASD
ConSEnSuS STATEmEnT
Now, with BYETTA, HbA
1c
reduction and
weight loss are both achievable goals
❍
Dose twice daily, within 1 hour before the 2 main meals
(at least 6 hours apart)
❍
Minimally invasive needle
❍
1 pen lasts for a full month
❍
After 1
st
month, switch to 10 µg pen
�
�
�
�
“I take pills for my diabetes, but it’s still progressing and I continue
to gain weight.”
“Isn’t there something that can help me gain control of both? ”
BYETTA is indicated for treatment of type 2 diabetes
mellitus in combination with metformin, and/or
sulphonylureas in patients who have not achieved
adequate glycaemic control on maximally tolerated
doses of these oral therapies:
Sustained HbA
1c
reductions
2
Progressive weight loss
2
Fixed-dose BD subcutaneous injection - 5 or 10 µg
●
●
●
Weight
HbA
1c
For the duration of therapy
10
mcg
Month 1
5
mcg
S3 Byetta 5 µg, 10 µg. Reg. No. 41/34/0068, 41/34/0069. 0.25 mg exenatide per ml.
For full prescribing information refer to the latest approved package insert.
References: 1. Nathan ��, Buse �B, �avidson �B, et al. �edical management of hyperglycaemia in type 2 diabetes:
A consensus algorithm for the initiation and adjustment of therapy. �iabetes care. 2008;31(12):1-11. 2. Klonoff �C,
Buse �B, Nielsen LL, Guan X, Bowlus CL, Holcombe �H, Wintle �E, �aggs �G. Exenatide effects on diabetes, obesity,
cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr
�ed Res Opin. 2008;24(1):275-286.
Eli Lilly (S.A.) (Pty) Ltd. Reg. No. 1957/000371/07
Private Bag X119, Bryanston, 2021
Telephone: (011) 510 9300
A2503 Nov 2010
Killian Webb 1283
